BUFFALO GROVE, Ill. -- Akorn today announced that the U.S. Food and Drug Administration (FDA) has granted approval for Akorn’s Abbreviated New Drug Application (ANDA) for Ofloxacin Ophthalmic ...
BUFFALO GROVE, Ill. — Akorn's abbreviated new drug application for ofloxacin ophthalmic solution 0.3% has been approved by the U.S. Food and Drug Administration, the company announced in a press ...
Ofloxacin ophthalmic solution is used in the treatment of keratitis corneal ulcers caused by susceptible Pseudomonas aeruginosa, Propionibacterium acnes, Serratia marcescens, Staphylococcus aureus, S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback